Pediatric Autoimmune Pancreatitis: Clinical Findings and Outcomes in Sweden

Miroslav Vujasinovic1,2, Fredrik Lindgren3,4, Nikolaos Kartalis3,5

  • 1Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Insights

Pediatric autoimmune pancreatitis (AIP) is rare, often involving multiple organs, especially inflammatory bowel disease (IBD). Glucocorticoid treatment leads to remission in most children with AIP and IBD.

Area of Science:

  • Pediatric Gastroenterology
  • Autoimmune Diseases
  • Pancreatology

Background:

  • Pediatric autoimmune pancreatitis (AIP) is a rare pancreatic disorder with unclear causes.
  • It is a risk factor for chronic pancreatitis in children.
  • This study examines a large Swedish cohort of pediatric AIP patients.

Purpose of the Study:

  • To describe the demographics of pediatric AIP patients.
  • To outline the clinical characteristics and outcomes of pediatric AIP.
  • To analyze treatment responses and long-term prognosis in pediatric AIP.

Main Methods:

  • Retrospective analysis of medical records for pediatric AIP patients.
  • Data collected from January 2006 to December 2022.
  • Inclusion criteria: diagnosis of pediatric AIP.

Main Results:

  • Thirty-seven pediatric AIP patients (mean age 13.5 years) were analyzed.
  • Most presented with mild acute pancreatitis (62.2%), multi-organ involvement (81.1%), and inflammatory bowel disease (IBD) (62.2%).
  • Eighty-four percent of treated patients achieved remission with glucocorticoids; exocrine insufficiency decreased from 43.2% to 24.3%.

Conclusions:

  • Pediatric AIP is rare and frequently co-occurs with IBD and multi-organ involvement.
  • Glucocorticoid therapy is effective, leading to remission in most cases.
  • Co-management of IBD may enhance outcomes for pediatric AIP patients.
Abstract